Latest news

• FDA rejects Amgen's osteoporosis hope romosozumab

  Tymlos is a parathyroid hormone-related protein (PTHrP) analogue that competes most closely with Eli Lilly's ageing osteoporosis drug Forteo (teriparatide) and could become a $1bn-plus product at peak, ... Forteo is heading for patent expiry, so Radius'

• CHMP recommends Merck & Co's Lantus biosimilar

  Also backs two biosimilar versions of Lilly’s osteoporosis therapy Forteo. EMA advisors have recommended Merck &Co's biosimilar version of Lantus, Sanofi's blockbuster basal insulin product, be approved. ... Forteo biosimilars. Meanwhile, the CHMP this

• Merck decision to drop odanacatib lifts UCB/Amgen

  Their anti-sclerostin antibody romosozumab is well ahead of other drugs in the emerging class and has been shown to be superior to Eli Lilly's big-selling osteoporosis therapy Forteo

• Amgen and UCB's romosozumab hits goals in male osteoporosis

  Forteo is widely used in osteoporosis therapy and brought in sales of around $1.35bn last year. ... Amgen and UCB previously reported data showing romosozumab was superior to Forteo, which also requires daily dosing by injection.

• Amgen says romosozumab on track for 2016 filing

  Amgen and UCB have previously reported data showing romosozumab was superior to Eli Lilly's parathyroid hormone-based Forteo (teriparatide), which requires daily dosing by injection. ... Forteo is widely used in osteoporosis therapy and brought in sales